论文部分内容阅读
服用短效口服避孕药是应用最广泛的避孕方法,避孕失败率最低(按意外怀孕计算),但仍然有50%的妇女在一年内停药。月经周期控制不好和体重增加是最常见的停药原因。这使得有必要改良口服避孕药配方,使其在维持可靠的避孕效果的同时在临床上更容易被接受。应用低剂量孕二烯酮和炔雌醇的大量临床经验显示其有良好的避孕效果和高度的耐受性。为了得到更多关于单相型孕二烯酮临床经验的数据,在巴西对285名门诊妇女进行了这个多中心研究。本研究主要评价敏定偶(30μg炔雌醇+75μg孕二烯酮)的避孕可靠性、周期控制情况和安全性。
Taking short-acting oral contraceptives is the most widely used method of contraception, with the lowest rate of contraceptive failure (calculated as unwanted pregnancies), but 50% of women still discontinue their treatment within one year. Poor menstrual cycle control and weight gain are the most common causes of discontinuation. This makes it necessary to modify oral contraceptive formulations to make them more clinically acceptable while maintaining a reliable contraceptive effect. A large number of clinical experiences with low doses of gestodene and ethinyl estradiol have shown good contraceptive efficacy and high tolerability. To get more data on the clinical experience with single-phase gestodene, 285 multicenter studies were conducted in Brazil for outpatients. This study mainly evaluated the contraceptive reliability, cycle control and safety of Minamata (30 μg ethinyl estradiol + 75 μg Gestodene).